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Abstract
Background: Greater trochanteric pain syndrome (GTPS) is a painful condition characterised by pain around the
greater trochanter usually affecting middle-aged women. The majority of patients will improve with conservative
management such as physiotherapy and non-steroidal anti-inflammatory drugs (NSAIDs); however, if this fails then
more invasive treatments including corticosteroid injections and surgery may be required. Platelet-rich plasma (PRP)
is an autologous blood product, which has a higher concentration of growth factors postulated to provide enhanced
healing and anti-inflammatory properties. There have been numerous studies on PRP’s efficacy in musculoskeletal soft
tissue conditions with similar pathology to GTPS, with varying results, most promising being in plantar fasciopathy and
patellar tendinopathy. Corticosteroids are the established second-line treatment, but do not always work long term.
PRP may be a suitable alternative to corticosteroid in GTPS with longer-term effects; however, there are very limited
reports. The Hip Injections PRP Vs Placebo (HIPPO) trial aims to assess the ability of PRP to improve symptoms and
function in patients with GTPS.
Methods/design: HIPPO is a single-centre, double-blind randomized placebo-controlled study in patients with a
radiologically confirmed diagnosis of gluteus medius or minimus tendinopathy with swelling within the tendon
insertion with or without bursitis. We aim to randomise 102 patients with GTPS to either the PRP or placebo
(normal saline injection) treatment arm. Participants will receive one ultrasound (US) guided PRP/placebo
injection into the trochanteric bursa and surrounding gluteus medius/minimus tendons. The primary outcome
measure is the International Hip Outcome Tool-12. Secondary outcome measures will include a visual analogue
score for pain, the three-level version of the EuroQol five-dimensional questionnaire and the modified Harris Hip
Score. Outcomes will be measured at baseline, 3, 6 and 12 months. Participants will have the option at 6 months
to have a repeat blinded injection or cross over to PRP. Analyses of primary and secondary outcomes will be
made according to the intention-to-treat principle. The trial reporting will comply with Consolidated Standards of
Reporting Trials (CONSORT) guidelines.
(Continued on next page)
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Discussion: The HIPPO study has been designed to test the hypothesis that PRP is effective in treating GTPS in
patients who have failed conservative management and to assess the duration of effect of PRP.
Trial registration: ClinicalTrials.gov, NCT03479190. Registered on 27 March 2018.
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Background
Overview
Greater trochanteric pain syndrome (GTPS), also known
as trochanteric bursitis, can be a debilitating condition
characterised by pain around the greater trochanter.
Pain increases on walking, squatting or climbing stairs
and when lying on the affected side or when crossing
one’s legs [1–3]. GTPS was a term adopted by Karpinski
et al. in 1985 instead of trochanteric bursitis as patients
did not exhibit typical bursitis signs of swelling, heat,
crepitus or fluctuation [4]. This notion has been sup-
ported by other studies [5] including a study performed
by Bird et al. 2001. They evaluated 24 patients using
magnetic resonance imaging with the clinical picture of
GTPS and found that the majority of patients had glu-
teus medius tendon pathology with only 2 patients with
isolated trochanteric bursal inflammation [1]. Hence,
GTPS instead of trochanteric bursitis appears to be the
more accurate way of describing the clinical condition,
which clearly may have multiple facets in its pathology.
A selection of non-surgical management options is
normally recommended, including rest, ice, stretching,
heat, strengthening and oral anti-inflammatory drugs.
The majority of patients improve with conservative
management; however, if this fails then more invasive
treatment options may be explored, including shockwave
therapy, corticosteroid injections [6–8] and even surgery.
Corticosteroid injection is an established second-line
treatment for GTPS that has been shown to be effica-
cious but not necessarily in the long term, as reported
by previously published studies [9]. This notion has been
supported by numerous reviews of GTPS management
[6, 10–12]. Surgery is usually set aside until the condi-
tion has become refractory and conservative measures
have been exhausted. Reports of PRP use as a novel
therapy in GTPS are very limited. A review of treat-
ments for GTPS by Buono et al. stated the following: “as
platelet rich plasma (PRP) has been widely used to
stimulate biological tendon healing in patients with
chronic tendinopathies, futures trends of research and
trials should focus on the application and effectiveness
of PRP for the management of GTPS” [11].
Existing knowledge
PRP is an autologous blood product, which has been
postulated to promote healing in damaged or inflamed
tissues including muscles, ligaments, bones and tendons.
Platelets contain a variety of elements including growth
factors and cytokines, which are involved in tissue heal-
ing. These include, platelet-derived endothelial growth
factor (PD-EGF), platelet-derived growth factor (PDGF),
transforming growth factor (TGF), insulin-like growth
factor (IGF), vascular endothelial growth factor (VEGF)
and basic fibroblast growth factor (bFGF). These growth
factors are present in the processes of tissue injury, in-
flammation and repair. Therefore, theoretically the higher
the concentration of platelets, the more growth factors
there will be present to promote the healing process when
administered directly to the area of interest [13].
PRP has been applied in other fields of medicine in-
cluding regenerative therapies in oral and maxillofacial
surgery [14, 15] Over the past decade or so there have
been numerous studies of the efficacy of PRP in treating
musculoskeletal conditions similar in pathology to
GTPS, such as lateral epicondylitis, patellar tendinitis,
rotator cuff pathology, Achilles tendinopathy and plantar
fasciopathy. This has been collectively reviewed by sev-
eral authors with reports of mixed efficacy compared to
standard treatments for these conditions with the most
promise shown in plantar fasciopathy and patellar ten-
donitis [16–18]. These reviews all mention the lack of
evidence to fully support or reject the efficacy of PRP in
these conditions, except for Achilles tendinopathy where
PRP showed no difference compared with placebo in a
randomised study [19, 20]. The healing or regenerative
properties of PRP have shown promise in other ortho-
paedic areas such as cartilage pathology [21].
Aims
The aim of the trial is to investigate the clinical efficacy
of the novel treatment platelet-rich plasma (PRP) in
treating patients with GTPS. The clinical efficacy of PRP
will be compared against a placebo injection of normal
saline.
Hypothesis
PRP is an effective treatment for greater trochanteric
pain syndrome.
The need for the trial
GTPS can be a painful and debilitating condition, which
as a last resort requires surgery especially if it does not
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respond to conservative treatment. This is clearly a de-
veloping field with a lack of published research with
on-going studies investigating the efficacy of PRP in
GTPS. Our trial differs from the other trials in its design
as we will compare PRP with placebo. Our aim is to
conduct a well-designed robust trial to establish whether
PRP is effective compared to placebo and what the dur-
ation of the effect is for patients suffering from GTPS.
Methods
Trial design
The trial will be a two-arm, single-centre, double-blind,
randomised control trial (RCT). The study will include a
two-way comparison between PRP and placebo normal
saline injections for treating GTPS. The trial design has
been based on our local experience with using PRP in
patients with GTPS and an RCT conducted by Monto et
al. in 2014 [22] comparing steroid injection with PRP in
patients with severe hip bursitis. Add to this, a pilot
study by Ribeiro et al. in 2016 [23], which compared the
efficacy of PRP against corticosteroid in the treatment of
GTPS.
Participants will be identified and referred for inclu-
sion in the study by their main care provider (general
practitioner (GP), orthopaedic surgeon, rheumatologist
or extended-scope physiotherapy practitioner). They will
then be invited for a first interview where eligibility will
be assessed, further information about the study will be
given and written consent for inclusion obtained. Poten-
tial participants will be permitted to reschedule another
interview appointment if they need more time to think
about whether they wish to participate. Participants will
be allocated randomly to either the PRP or normal saline
injection treatment arm. They will receive their treatment
under sterile conditions under ultrasound guidance by a
consultant rheumatologist (IA). The participant will be
contacted by phone a week after receiving treatment to
monitor for early adverse events. Participants and out-
come assessors will be blinded to treatment arm. Partici-
pants will be reviewed at baseline, 3, 6 and 12 months
with patient-reported outcome measures (PROM) com-
pleted at each of these reviews. During the 6 months fol-
low up participants will be given the option of a repeat
injection of their original treatment or if they specifically
request PRP then we will offer this to them but maintain
the blinding of their original treatment. This was a key
ethical discussion point in our focus group meeting en-
gaging patient and public involvement in that expecting
participants to potentially continue with placebo for a fur-
ther 6 months while in pain would place a significant bur-
den on them. The trial is expected to last approximately 4
years allowing 18–24 months for recruitment with the
remaining time used to complete the follow up period
until the last patient recruited.
The feasibility and scientific quality of the trial has been
peer-reviewed and approved by the Principal Investigator
(PI) and Research and Development team. The ethical ap-
proval was granted by Health Research Authority (HRA)
England and the trial is listed with the number 198415.
The trial protocol will permit its reporting in line with the
Consolidated Standards of Reporting Trials (CONSORT)
guidelines [24]. [The Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) checklist is
provided as Additional file 1].
Recruitment
The source of recruitment will be from their main care
provider (GP, orthopaedic surgeon, rheumatologist or
extended-scope practitioner). Following the first interview
and consent to enter the trial, eligibility checks (Table 1)
will be repeated for each participant on the day they attend
for treatment, to ensure that participants are not rando-
mised in error. The participant will receive confirmation of
their inclusion in the trial, which will also be recorded in
their medical notes. Their GP will be informed.
Table 1 Inclusion and exclusion criteria
Inclusion criteria:
Over 18 years of age
Symptoms consistent with GTPS present for at least 6 months
Radiological diagnosis of GTPS using MRI, or ultrasound scan if MRI
contraindicated
Failed conservative management in any other care setting
Patient is willing and able to provide written informed consent.
Exclusion criteria:
Lacks capacity to provide consent
Has hip joint osteoarthritis demonstrated on a plain radiograph,
requiring treatment
Presence of confounding pathologies on the hip MRI
Any extensive surgery or deformity of the hip demonstrated on x-ray
Presence of systemic disorders – coagulopathy, active infection,
immune system disorders, peripheral neuropathy, malignancy,
unresolved fractures
Had any surgical treatment specifically targeted at GTPS e.g.
bursectomy/ilio-tibial band lengthening
Pregnancy
Anti-coagulant therapy e.g. warfarin, rivaroxaban, apixaban, dabigatran
Haemaglobin < 10 g/dl or platelets < 150,000/ul
Unable to safely stop anti-platelet/NSAID medications e.g. recent
cardiac stenting
Has lumbar-sacral spine pathology or a recent history of acute hip
trauma
Has a recent history of acute sciatica
Is not able to attend or comply with treatment or follow up
scheduling
Participates in any other clinical trial
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Consent
All potential participants will attend a first interview
meeting with our research team following referral from
their primary care provider (e.g. GP/orthopaedic sur-
geon/rheumatologist). They should already have received
the trial information sheet. We will explain the purpose
and nature of the trial again and assess their eligibility.
They will be given up to a week to decide whether they
wish to be entered into the trial. A second interview will
be rescheduled if necessary. Written consent to enter
the trial will be obtained. Once the participant has con-
sented, their baseline PROMs will be assessed and
recorded.
Treatment allocation
Sequence generation
The allocation sequence will be generated randomly using
an online computer-generated randomiser (https://seale
denvelope.com/). The participant will be allocated to either
the PRP or normal saline arm of the trial. All injections will
be performed by the same consultant rheumatologist who
will be not involved in the data collection process.
Allocation concealment
The allocation sequence will be hidden from the PI and
outcome assessors. Their allocation will be recorded on a
separate database to which the PI/outcome assessors will
not have access. Only the treatment administrator (con-
sultant rheumatologist) will have access to this so they
know what treatment they are issuing. They and a dedi-
cated research nurse will be guardians of this allocation
sequence database to ensure that the patients, PI and out-
comes assessors do not have access. Allocation will be re-
vealed once the trial has ended and data analysis begins.
Allocation implementation
Participants will be enrolled by our research team lead
by the PI (AM). They will have been allocated their
treatment randomly. Allocations will be held on a secure
database which the treatment administrator (consultant
rheumatologist (IA)) will have access on the day of their
treatment.
Blinding
All participants will be blinded to the treatment alloca-
tion. All treatments will be prepared in another room
and the patient will have a screen between them and
their hip preventing them from seeing what treatment
they are being given. The treatment administrator will
not be blinded. Outcome assessors will be blinded.
Trial treatments
All participants will attend the hospital as a day case. As
per Northumbria Healthcare NHS Foundation Trust
policies, written consent will be obtained for their pro-
cedure, which will be generic to cover both treatment
arms. All participants will have 40 ml of blood drawn
using an aseptic technique, which will then be taken to
another room for 20 min to simulate the centrifuge time
for the PRP preparation, regardless of which treatment
they are receiving. They will also have a drape obscuring
their hip and treatment area from their line of sight. All
these measures are to maintain blinding of the partici-
pant to treatment allocation. The procedure will take
place in sterile conditions to minimise the risk of infec-
tion. They will have local anaesthetic infiltrated superfi-
cially and deep in the greater trochanter area. Our
consultant rheumatologist will then inject either PRP or
normal saline under ultrasound guidance into the tro-
chanteric bursa and abductor tendons (2 ml in the ab-
normal tendon and 2 ml in the bursa). All participants
will then be advised to rest for 72 h and will be referred
for physiotherapy.
Participants will be randomised into 2 groups:
1. Test: PRP treatment using the SW-PRP system
provided by NTL Biologica – 40 ml of the
participant’s own blood is added to 6 ml of ACD-A
(Anticoagulant Citrate Dextrose Solution, Solution
A). This is then placed into the SW-PRP Syringe
Device. The vial is centrifuged at 3850 rpm for
7 min. Red blood cell fluid level in the device is
optimised and then centrifuged for a further
4 min at 3850 rpm. Platelet-poor plasma is
extracted from the device and discarded. The
remaining PRP is extracted from the buffy coat
layer; 4 ml of PRP is withdrawn and is ready for
administration.
2. Placebo: 4 ml of normal 0.9% saline.
Physiotherapy
The physiotherapy protocol will include stretching exer-
cises, which consist of gluteal, iliotibial band and pirifor-
mis stretching. Prone lumbar extension, supine lumbar
rotation and cat stretch exercises will also be included.
These are accompanied with strengthening exercises
such as side-lying leg lift, clam, gluteal kickback and bal-
ance exercises. This will be a general standardised
physiotherapy regime and will be standardised across
our physiotherapy requests. Naturally the physiotherapy
that participants receive may vary, such as by the fre-
quency of sessions, and we accept this as a variable that
could influence outcome; however, measures will be
taken to minimise this as much as possible.
Measure of harm and adverse events
Participants will be monitored for adverse events at
each follow up. One week after their treatment each
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participant will receive a phone call to monitor early
adverse events. Adverse events will be reported in the
study publication.
Expected potential adverse events:
 Pain
 Infection
 Failure to relieve/recurrence/progression of
symptoms/exacerbation
Outcome measures
Primary
The International Hip Outcome Tool–12 (iHOT-12)
PROM scores at baseline, 3, 6 and 12 months will be
compared within and between the PRP and normal sa-
line arms.
Secondary
The visual analogue score (VAS) for pain, the Modified
Harris Hip Score (mHHS) and the three-level version of
the EuroQol five-dimensional (EQ-5D 3 L) questionnaire
PROM scores will be collected at baseline, 3, 6 and
12 months and will be compared within and between
the PRP and normal saline arms (Fig. 1).
End of the trial
Recruitment will cease once the last participant has been
recruited following our sample size recommendations.
The trial will cease once the last patient has attended
their 12 months follow up (Fig. 2).
Data management
The data collected from the trial will be entered into a
trial database. The database will be agreed and set up by
our information technology (IT) technician, statistician
and PI. The database will be stored securely on our
computer systems in the hospital. During the interim
analysis, the database will be frozen to ensure data col-
lected after this point are not included in the interim re-
port. Access to the data will be limited to those only
directly involved in the trial and who are part of the re-
search team. The data will be anonymised in terms of
participant identifiable data and will only contain demo-
graphic details. Identifiable participant data will be held
on a separate database in our secure computer network
in the hospital. Each participant will have a unique par-
ticipant code so their outcome data can be matched with
their personal identifiable data if required. All physical
data will be stored in the Research and Development Of-
fice, North Tyneside General Hospital in a locked cabi-
net. The office is secured by a code-operated lock and is
only accessible by the research team. All computer data
will be stored on our secure password-protected Na-
tional Health Service (NHS) Trust computers. Data will
be archived in accordance with the Research and Devel-
opment Department, Northumbria Healthcare NHS
Foundation Trust guidance. A data monitoring commit-
tee will be formed and will convene for this trial.
Data Monitoring Committee
A Data Monitoring Committee will convene at the in-
terim period of 50% recruitment at 6-month follow up.
This will be chaired by the PI and include other
co-investigators, a trial coordinator and ideally a mem-
ber of our patient focus group. All issues relating to the
management and conduct of the trial will be reviewed
and addressed. Meeting times will be an interim meeting
at 50% recruitment reaching 6-month follow up and the
end of trial.
Statistical analysis
Statistician report
The primary outcome of interest is the change from
baseline to 12-month follow up in the iHOT-12, com-
paring the PRP and placebo group. The study will be
run as a superiority trial. The cut-off for statistical sig-
nificance is set at 5% and desired power at 90%, with
two-tailed tests applied. Data on change from baseline
are also assumed to be parametric and the t test will be
applied to the data to assess statistical significance.
The minimally clinically important difference (MCID)
for the iHOT-12 has been reported by Sansone et al. as
10 (from 100) and the standard deviation for the change
in score from baseline as no greater than 21 [25]. Al-
though, there are few previous data on which to base a
sample size calculation, Monto et al. compared change
from baseline to 12-month follow up in a group of 40
patient with hip bursitis, with steroids and PRP as the
interventions being compared. In the PRP group Harris
Hip scores increased from 51.7 to 87.4 whilst in the ster-
oid group, scores increased from 50.5 to 58.8 at
12 months [22]. Since the Harris Hip score is also scored
from 100, our sample size calculation is based on these
figures. We conservatively assume that change in iHOT
score from baseline in the placebo group will be no
more than in the steroid group reported by Monto et al.,
and estimate a maximal change of 10. We also estimate
that the change in the iHOT score from baseline in the
PRP group will be no less than 27. Using these figures, a
minimal sample size at follow up of 66 (33 in each
group) will be required.
Pilot data obtained by our team suggest that the rate
of refusal to participate should be no more than 25%
and the dropout rate no more than 35% over 12 months.
Refusal rates tend to be low in this patient group given
the chronic nature of the condition and the fact that pa-
tients will only be approached once conservative man-
agement has failed. Thus, we will need to approach
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135.4 (rounded up to 136) patients, and recruit 102 pa-
tients to achieve our target sample size.
Data will be analysed using standard statistical soft-
ware (e.g. SPSS and SAS). In the first instance, data will
be analysed using simple descriptive statistics to com-
pare the two groups in terms of demographics, clinical
characteristics at baseline and outcomes. The primary
outcome of interest will be the change from baseline to
12-month follow up in the iHOT-12, comparing the PRP
and placebo group. The iHOT-12 data are expected to
be parametric and so the unpaired t test will be used to
compare the difference in change from baseline in the
Fig. 1 Standard protocol items: recommendation for interventional trials (SPIRIT) flow diagram. A summary of the planned study interventions
and assessments. MRI, magnetic resonance imaging; iHOT-12, International Hip Outcome Tool-12; VAS, visual analogue score; EQ-5D 3 L, Three-level
version of the EuroQol five-dimensional questionnaire; MHHS, Modified Harris Hip Score; PRP, platelet-rich plasma
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two groups. Since randomisation will not be stratified,
we will also look to adjust for the possible confounding
influence of differences in baseline characteristics (e.g.
age, gender and body mass index (BMI)) using multivari-
able methods (e.g. linear regression). The significance
level for all inferential tests will be set at 5%.
In secondary analysis, we will investigate changes in
visual analogue pain score, EQ-5D 3 L and modified
Harris Hip score in the two groups, as for the primary
outcome. In sub-group analysis, we will investigate the
data based on specific previous treatment, patients who
required more than one treatment and patients with the
highest levels of baseline pain.
The test group (PRP) alone: for all outcome measures
the difference between the follow up scores with base-
line will be assessed (e.g. baseline versus 3 months,
baseline versus 12 months). The difference between
one follow up period to the next will be examined (e.g.
3 months versus 6 months, 6 months versus 12 months).
A significant difference will be set at a p value of less
than 0.05.
The placebo group (normal saline) alone: data will be
analysed as for the test group, as described.
Test versus placebo: for all outcome measures, the dif-
ferential change at each follow up time point will be
compared between the trial arms and the significance
value calculated.
Statistical tests will be performed to ensure that gen-
der, BMI and age differences are not significantly associ-
ated with a particular result. Care will be taken to
minimise missing responses and to continue to follow
up those who withdraw from treatment.
We will only be using the completed cases for final
analyses; the remainder will be excluded.
Discussion
Platelet-rich plasma (PRP) is an autologous blood product,
which has a higher concentration of growth factors postu-
lated to provide enhanced healing and anti-inflammatory
properties. There have been numerous studies on the effi-
cacy of PRP in musculoskeletal soft tissue conditions with
similar pathology to GTPS, with varying results, the most
promising being in plantar fasciopathy and patellar tendi-
nopathy. Corticosteroids are the established second-line
treatment, but do not always work long term. PRP may be
a suitable alternative to corticosteroid in GTPS, with
longer-term effects; however, there are very few reports
discussing its efficacy. Lee et al. in 2016 [26] prospectively
studied the efficacy of intra-tendinous PRP injections as
treatment for chronic recalcitrant gluteus medius tendino-
pathy. They found ultrasound-guided intra-tendinous PRP
injections to be a safe and effective treatment option for
chronic recalcitrant gluteus medius tendinopathy due to
moderate to severe tendinosis. A second report by
Ribeiro et al. from Brazil [23] was published in 2016
comparing the efficacy of PRP against corticosteroids.
They concluded that during the first 2 months, which
was the study period, the PRP has no influence on pain
relief and functional improvement in trochanteric syn-
drome. Again in 2016 a third report from the USA
compared ultrasound-guided percutaneous tendon fen-
estration to PRP injection for treatment of GTPS [27].
The report concluded that both ultrasound-guided ten-
don fenestration and PRP injection are effective for
treatment of gluteal tendinosis, showing symptom im-
provement in both treatment groups. Large effect sizes
were evident in these studies. We calculated these based
on Cohen’s test, taking some statistical assumptions into
account, given that all data were not available. The effect
Fig. 2 Study flow chart. GTPS, greater trochanteric pain syndrome; R&D, Research and Development; PROM, patient-reported outcome measure;
PRP, platelet-rich plasma; physio, physiotherapy
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sizes in the study of Lee et al. were 1.303, 1.052, 0.883 and
1.677 for the mHHS, Hip Outcome Score (HOS) activities
of daily living, HOS sport and HOT-33, respectively. The
effect sizes in the study of Ribeiro et al. were 1.155, 1.371
and 1.509 for the Facial Expressions Scale for Pain at fol-
low up of 10, 30 and 60 days.
Prior to these reports, Mautner et al. conducted a study
in 2013 [28] to assess whether ultrasound-guided PRP in-
jections are an effective treatment for chronic tendinopa-
thies. The study included 180 patients of whom16 had
gluteus medius tendinopathy. The majority experienced
significant improvement in symptoms, evidenced by 82%
of patients reporting at least moderate improvement of
their symptoms. A similar satisfaction rate of 85%was also
found, respectively, demonstrating that the improvement
in symptoms likely resulted in patient satisfaction. There
are no randomised trials in the current literature and all
these published reports were based on short follow up pe-
riods and small numbers of patients.
This paper describes the rationale and design for the
first randomised trial that aims to determine the effect-
iveness of PRP in the treatment of greater trochanteric
pain syndrome. No previous trials have assessed PRP
against placebo or measured clinical outcomes beyond 6
months. The HIPPO trial will make a significant contri-
bution to the evidence base available to support effective
conservative management of GTPS.
Current status of the trial
The trial is currently running. Recruitment and treat-
ment started in spring 2018.
Additional file
Additional file 1: Standard protocol items: recommendation for
interventional trials (SPIRIT) 2013 checklist. Recommended items to
address in a clinical trial protocol and related documents. (DOC 121 kb)
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